drospirenone/ethinyl estradiol / Generic mfg. - LARVOL DELTA

A Multicentre Observational Cohort Study: The Effectiveness of Ethinyl Estradiol/Drospirenone (YAZ) 24+4 in Bleeding control and menstrual cycle regulation in patients with AUB-O of different bleeding intensities (ChiCTR) - P=N/A | N=240 | Not yet recruiting | Sponsor: West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University

New trial • Women's Health

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood (clinicaltrials.gov) - P1 | N=36 | Suspended | Sponsor: Boehringer Ingelheim | Recruiting ➔ Suspended

Trial suspension

Hemostatic safety profile of estetrol vs. ethinylestradiol in oral contraceptives: a systematic review and meta-analysis. (PubMed, Rev Bras Ginecol Obstet) - "To evaluate the hemostatic profile of estetrol/drospirenone (E4/DRSP) compared with ethinylestradiol/drospirenone (EE/DRSP) in adult women. E4/DRSP demonstrates a more favorable hemostatic profile than EE/DRSP, potentially reducing thrombotic risk. Despite the limited number of RCTs, consistency across markers supports E4 as a safer estrogenic component for contraceptive formulations, with implications for women at increased risk of venous thromboembolism.PROSPERO registry: #CRD420251074961."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Venous Thromboembolism • PROS1

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

Association of High-Sensitivity C-Reactive Protein With Metabolic but Not Endocrine Parameters in Women With Polycystic Ovary Syndrome (ASRI 2026) - "After 1 year of treatment, no significant difference in hs-CRP levels was observed between the oral contraceptive group (drospirenone/ethinyl estradiol; Yaz®, Bayer AG, Germany) and the cyclic progestin group (medroxyprogesterone acetate 10 mg; Provera®, Pfizer Italia S.r.l., Italy). In women with PCOS, hs-CRP levels were significantly associated with metabolic parameters but not with endocrine parameters, including hyperandrogenemia. In women with PCOS, hs-CRP levels were significantly associated with metabolic parameters but not with endocrine parameters, including hyperandrogenemia. These findings suggest that hs-CRP may serve as a potential marker of metabolic risk in this population. Further prospective studies are warranted to clarify its clinical implications."

Clinical • Diabetes • Endocrine Disorders • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Type 2 Diabetes Mellitus • CRP

Analysis of drug-induced pulmonary embolism risk based on the Food and Drug Administration Adverse Event Reporting System database. (PubMed, J Thorac Dis) - "The highest number of PE cases was reported for drospirenone/ethinylestradiol, rivaroxaban, and ethinylestradiol/etonogestrel. Through a comprehensive analysis of the FAERS database, this study identified multiple drug categories that exhibit significant positive associations with PE. These findings suggest that clinicians should be vigilant about these potential risk signals, particularly when prescribing long-term treatments to patients with underlying thrombotic risk factors."

Adverse events • Journal • Cardiovascular • CNS Disorders • Oncology • Pulmonary Embolism • Respiratory Diseases

Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65 years: Based on the FDA adverse event reporting system (FAERS). (PubMed, Res Social Adm Pharm) - "This analysis identifies antibiotics, immunosuppressants, and hormonal agents as drugs with prominent DILI disproportionality signals in adults aged 18-65 years. The findings advocate for targeted hepatic monitoring and suggest that drug labels could reflect class-specific latency patterns. Sex-specific signal monitoring warrant further investigation."

Adverse events • Journal • Real-world evidence • Hepatology • Liver Failure • Pain

Hormonal therapies for post-abortion uterine recovery: Comparison of estradiol ± dydrogesterone, transdermal estradiol gel and combined oral contraceptives. (PubMed, Pak J Pharm Sci) - "This study provides direct comparative evidence that specific hormonal regimens offer distinct benefits for post-abortion recovery. For women seeking contraception through drospirenone and ethinyl estradiol tablets are valuable for shortening bleeding and promoting menstrual regularity. For those with future fertility goals, estradiol gel is valuable for significantly enhancing endometrial regeneration. All regimens demonstrated good safety, enabling personalized clinical decision-making to improve patient outcomes after induced abortion."

Clinical • Journal • Hematological Disorders • Infectious Disease • Infertility • Sexual Disorders

Treatment of premenstrual dysphoric disorder with continuous versus intermittent dosing of SSRI/SNRI verses oral contraceptives - a systematic review (APA 2026) - "SSRIs/SNRIs remain well evidence-supported as first-line treatment for PMDD, with moderate to large effect sizes vs placebo. COCPs with drospirenone + ethinyl estradiol also show benefit over placebo but with smaller to moderate effect sizes, and more adverse effects. Direct comparative trials of SSRIs/SNRIs vs COCPs are scarce; thus clinicians must choose based on patient preference, side-effect profiles, comorbidities, and need for contraception."

Review • CNS Disorders • Depression • Mood Disorders

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

Trial initiation date • Oncology

Exploring the molecular crosstalk between the sex steroids drospirenone and ethinylestradiol with vaginal lactobacilli. (PubMed, Front Microbiol) - "This interaction may contribute to the maintenance of vaginal eubiosis and has potential implications for the development of microbiome-targeted strategies to support women's health. Further studies are needed to elucidate the broader functional consequences of hormone-microbiota interactions and their clinical relevance."

Journal • Infectious Disease • Women's Health

CoCo3-PCOS: CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20g+DRSP, and DRSP-only in women with PCOS (clinicaltrialsregister.eu) - P4 | N=156 | Not yet recruiting | Sponsor: Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu

New P4 trial • Polycystic Ovary Syndrome

Rapidly Progressive Dementia Associated with ASIA Syndrome (AAN 2026) - "She also reported mild to moderate polyarthralgia, treated symptomatically with intravenous hydrocortisone. In addition to the above, her husband noted progressive cognitive and functional decline. Her medical history included polycystic ovary, insulin resistance, use of combined oral contraceptives (drospirenone and ethinylestradiol), bilateral silicone breast implants, and smoking...Conclusions This case emphasizes the need to consider ASIA syndrome in patients presenting with unexplained cognitive decline and seizures, particularly in the context of silicone breast implants. Remarkably, studies have reported that 50-98% of patients experienced improvement of silicone-related complaints after explantation."

Alzheimer's Disease • Ataxia • CNS Disorders • Dementia • Epilepsy • Huntington's Disease • Immunology • Movement Disorders • Musculoskeletal Pain

Progesterone Hypersensitivity, an Uncommon Cause of Dermatitis after Etonogestrel Implant Removal (AACE 2026) - "She subsequently transitioned to drospirenone-ethinyl estradiol combined oral contraceptive and discontinued cabergoline. Timing is a critical clue: flares usually occur during the luteal phase of the menstrual cycle when progesterone levels rise, with improvement following the onset of menses as progesterone declines. Known triggers for progesterone hypersensitivity"

Cough • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases

CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial comparing E4+DRSP, EE 20?g+DRSP and DRSP-only (clinicaltrialsregister.eu) - P4 | N=156 | Not yet recruiting | Sponsor: Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu

New P4 trial

Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill (clinicaltrials.gov) - P3 | N=98 | Not yet recruiting | Sponsor: Dr. Hang Wun Raymond Li

New P3 trial

CDAK539A12102: A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer (clinicaltrialsregister.eu) - P1 | N=9 | Not yet recruiting | Sponsor: Novartis Pharma AG

New P1 trial • Oncology

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2029 ➔ Apr 2028 | Trial primary completion date: Nov 2029 ➔ Mar 2028

Trial completion date • Trial primary completion date • Oncology

Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug-Drug Interaction Study. (PubMed, Clin Drug Investig) - P1 | "Ensitrelvir has no clinically meaningful effect on the pharmacokinetics of EE and drospirenone, and the combination was well tolerated. These findings support the co-administration of ensitrelvir with COCs in clinical practice."

Journal • P1 data • PK/PD data

Evaluating the Impact of Progestin Choice in Combined Oral Contraceptives on Acne Treatment Escalation (AAD 2026) - "The index exposure was first prescription for drospirenone/ethinyl estradiol, norgestimate/ethinyl estradiol, or levonorgestrel/ethinyl estradiol... Compared with levonorgestrel-containing COCs, drospirenone was associated with a significantly lower risk of treatment escalation, including reduced initiation of doxycycline/minocycline, spironolactone, and isotretinoin... Drospirenone-containing COCs appear more effective for acne control compared with norgestimate and levonorgestrel formulations. These findings provide evidence to guide contraceptive selection among patients seeking dual benefits of contraception and acne treatment."

Acne Vulgaris

Effect of orlistat and anti-androgen oral contraceptives on pregnancy outcomes in overweight or obese PCOS patients during comprehensive management. (PubMed, Arch Gynecol Obstet) - "This study demonstrates that preconception combination therapy with DRSP/EE and orlistat significantly reduces the risk of GDM in overweight or obese women with PCOS. DRSP/EE monotherapy also exhibits a potential protective trend, although the effect is less robust compared to the combination regimen. While differences in HDP and other pregnancy outcomes did not reach statistical significance, the combination therapy group yielded the most favorable clinical profile, achieving the numerically highest live birth rate and the lowest incidence of adverse pregnancy outcomes. Comprehensive management targeting BMI and metabolic indicators is crucial for improving pregnancy prognosis in this population."

Journal • Diabetes • Gestational Diabetes • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome

Effects of dienogest and combined oral contraceptives treatment on small ovarian endometriomas (ISGE 2026) - "Interventions: Group A received combined oral contraceptives containing drospirenone 3 mg/ethinyl estradiol 0.02 mg in a 24/4 regimen, while Group B received dienogest 2 mg once daily. Although dienogest led to a greater reduction in cyst size compared to COCs, both treatments effectively suppressed disease progression and alleviated pain. These findings support the use of both dienogest and COCs as effective non-surgical therapeutic options for small ovarian endometriomas."

Endometriosis • Gynecology • Musculoskeletal Pain • Women's Health

Turner Syndrome: A Case Report Highlighting Diagnostic and Therapeutic Challenges in Hormone Replacement Management (ISGE 2026) - "She had received various estrogen preparations; after menarche, combined hormonal contraceptives (ethinylestradiol with drospirenone) and HRT regimens (estradiol hemihydrate with drospirenone or estradiol valerate with levonorgestrel) were used, all associated with abnormal uterine bleeding (AUB). This case report illustrates the importance of thorough evaluation and personalized hormone replacement therapy in women with Turner syndrome to ensure symptom control and optimal quality of life."

Case report • Clinical • Genetic Disorders • Gynecology • Turners Syndrome • Women's Health